Indivior announced on Monday that it has reached an agreement to settle a multi-district Suboxone litigation case in the United States, agreeing to pay $385 million to resolve the claims.
The litigation at the center of this case revolved around allegations that Indivior engaged in practices to impede generic competition for Suboxone, an opioid addiction treatment, in an effort to maintain its market dominance.
Indivior is prepared to disburse $385 million, and this will result in a charge of $228 million during the third quarter, which will be excluded from the adjusted earnings.
In a statement, the company explained, “This charge represents the additional amount above the current remaining provision of $157 million for the antitrust multi-district litigation, which reflects the previously announced settlement agreements with the states and end payors. The agreement will become final once approved by the court. Payment of the $385 million is expected to be made in November 2023 and funded from Indivior’s existing cash.”
Read more: Indivior Must Face Opioid Antitrust Suit
This settlement brings the multi-district litigation to a close, contingent on approval by the United States District Court for the Eastern District of Pennsylvania. Consequently, a trial, which had been set to commence in the near future, has been canceled.
Mark Crossley, the Chief Executive Officer of Indivior, commented, “We are pleased to achieve this settlement to conclude this legacy multi-district antitrust matter. The resolution of this litigation, which was filed over a decade ago, provides greater certainty for all Indivior stakeholders and allows us to continue focusing on our important work for patients suffering from opioid use disorder and mental health illnesses around the world.”
It’s worth noting that Indivior was previously part of Reckitt Benckiser Group PLC before being spun out as an independent company in late 2014.
In addition to this settlement news, Indivior also provided guidance for the third quarter and full year. They anticipate net revenue between $268 million and $273 million for the third quarter, representing a 17% year-on-year increase at the midpoint.
Source: AJ Bell
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI